PF-Atlas › Clinical Trials › NCT04680832
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
Electronic nose · Not specified
Registry ID
NCT04680832
Phase
Not specified
Status
Active, not recruiting
Drug / intervention
Electronic nose
Sponsor
Erasmus Medical Center
Start
2020-11-01
Enrollment
600
Locations
5
About this trial
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic interstitial lung diseases. The value of eNose as biomarker for disease progression and response to treatment is also assessed. Besides, validity of several questionnaires for pulmonary fibrosis is investigated.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04680832 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.